FibroBiologics: Advancing Next-Gen Therapies for Chronic Disease | Market Potential & Innovation
Jun. 27, 2025
FibroBiologics (Nasdaq: FBLG) is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.
